Multiple myeloma preparative regimens for high-dose therapy and autologous transplantation: what's new?
High-dose chemotherapy and autologous stem cell transplantation remains a standard procedure in relatively young and selected older patients with multiple myeloma. High-dose melphalan has remained the chemotherapeutic agent of choice based on earlier prospective randomized trials. Despite investigations involving different combinations of chemotherapeutics, radiation and novel agents with and without melphalan, none of these alternative preparative regimens have demonstrated superiority to high-dose melphalan used as a single agent in multiple published studies. In this article, we review the published literature regarding preparative regimens used in patients with multiple myeloma undergoing autologous stem cell transplantation.
The Blood & Marrow Transplant Program, University of Kansas Medical Center, Kansas City, KS, USA; 2330 Shawnee Mission Pkwy, Westwood, KS 66205, USA.
Omar S
OS
Aljitawi
Joseph P
JP
McGuirk
D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D008558:Melphalan